21SEP

Four funding calls open in a fortnight

3 min read

16:52UTC

UKRI, Innovate UK and ARIA opened or expanded four programmes between 5 and 20 August, including the first route for companies to sponsor overseas researchers directly.

← Back to Nscale takes $103.4bn of contracts to NYSE Jump to analysis ↓

TechnologyDeveloping

Key takeaway

UKRI, Innovate UK and ARIA opened four programmes on schedule between 5 and 20 August.

UK Research and Innovation (UKRI) opened the Global Talent visa's endorsed funder pathway to more than 100 research-intensive businesses on 6 August, the first time companies rather than institutions can sponsor overseas researchers directly⁠¹. The pathway has moved over 12,500 people from more than 130 countries into UK research careers to date. For a founder trying to hire a specialist researcher, this replaces the standard skilled-worker route with a visa the company can endorse itself.

Innovate UK announced its largest-ever Women in Innovation cohort on 5 August: 61 winners at £75,000 each plus twelve months of support, with a further 39 highly commended founders taking the support without the cash⁠². The Advanced Research and Invention Agency (ARIA), Britain's high-risk research funder, opened the first funding call of its £65m olfactory perception programme on 12 August, run by programme director Claire Donoghue, which is trying to give machines a sense of smell good enough to detect food spoilage and disease⁠³. UKRI launched a £28m Ultra-Long Duration Energy Storage Challenge on 20 August for technology that can supply clean electricity for 100 hours or more⁠⁴.

Four programmes in a fortnight is an ordinary cadence rather than a surge; Innovate UK closed its Createch competition and opened Advanced Connectivity Technologies in the same manner in July, and ARIA has been running programme calls on its own schedule since the Scaling Inference Lab work with AMD in June. No competition in this window was paused, no deadline slipped and no grant went unpaid on any record we can read. The point is the contrast: the layer that writes competitions and pays grants moved to the new department weeks ago, while the layer that records who sponsors UKRI has not.

Deep Analysis

In plain English

Four different bits of government research funding all moved in the same three weeks in August. UKRI, the main funder, opened up a visa route letting tech and science companies, as well as universities, sponsor skilled researchers from abroad to come and work for them directly. Innovate UK gave its biggest ever batch of grants, £75,000 each, to 61 women running innovative businesses. ARIA, a newer, more experimental funding agency modelled on a similar US body, opened its first grant call for research into giving machines a sense of smell, useful for things like detecting spoiled food or diagnosing disease early. And UKRI put £28m into technology that can store clean electricity and release it steadily for 100 hours or more, far longer than a normal battery. None of this required anyone to know which government department is technically in charge of UKRI right now, which is the point: the money kept moving even while the paperwork about who is accountable for it did not.

Deep Analysis

Root Causes

Grant competitions and visa-pathway changes are drafted and budgeted months ahead of launch, through Spending Review allocations and programme business cases that predate any single minister or department. That is why four programmes from three different bodies, UKRI, Innovate UK and ARIA, can open in the same fortnight even while the departments that sponsor them cannot agree which one exists on paper, the gap documented elsewhere in this briefing.

ARIA's £65m olfactory programme in particular depends on the agency's statutory independence from normal Research Councils UK peer review, granted by the ARIA Act 2022, which is what let programme director Claire Donoghue commit funding without the multi-stage approval UKRI's own councils use.

What could happen next?

Meaning
Grant delivery across UKRI, Innovate UK and ARIA is running independently of the unresolved sponsorship dispute over who oversees UKRI.
Opportunity
Businesses can now sponsor overseas researchers directly under the Global Talent visa pathway for the first time, rather than routing through a research institution.

Source Landscape

This story draws on neutral-leaning sources

Primary parallel: UKRI's Global Talent visa pathway has been expanded before, widening eligible research fields and adding fast-track processing in earlier years; each change moved administrative eligibility rather than funding, the same category of change as this one, letting businesses rather than institutions sponsor researchers for the first time.

Counter-parallel: ARIA's olfactory perception programme has no earlier UK state-funded precedent; the agency, modelled on the US Defense Advanced Research Projects Agency, was created under the ARIA Act 2022 specifically to fund research too speculative for UKRI's peer-review model, so this call tests a newer institutional mechanism rather than an established one.

Consensus view: ARIA's olfactory perception programme, run by programme director Claire Donoghue, joins UKRI's Global Talent visa expansion and Ultra-Long Duration Energy Storage Challenge as evidence that the agencies' grant-making machinery kept operating through the sponsorship uncertainty documented elsewhere in this briefing.

Counter-view: No published outside assessment weighs whether four programmes opening inside a fortnight reflects a genuine acceleration in innovation policy or a scheduling artefact, grant cycles set months in advance landing together by coincidence. The unattributed case for coincidence: three of the four, the visa pathway, the Women in Innovation cohort and the energy storage challenge, sit inside forward calendars UKRI would have set before the department rename.

Key tension: Whether the four-programme cluster demonstrates that agency delivery is now decoupled from departmental sponsorship, or whether it simply reflects pre-committed grant cycles that would have landed on these dates regardless.

Sources:UK Research and Innovation·UK Research and Innovation·Advanced Research and Invention Agency

Mentions:UKRI →Innovate UK →Advanced Research and Invention Agency →Advanced Connectivity Technologies →Scaling Inference Lab →Createch →

First Reported In

Update #14 · UKRI's sponsor department no longer exists

UK Research and Innovation· 24 Aug 2026

Read original →

Causes and effects

Caused by

Clifford quits ARIA chair for Anthropic

Clifford's resignation leaves ARIA's August funding programmes, including the olfactory perception call, without a permanent chair.

Occurred 7 Sept 2026

Read story →

This Event

Four funding calls open in a fortnight

The delivery layer kept issuing competitions on schedule through the fortnight, whatever the sponsorship records said.

Different Perspectives

Abu Dhabi Investment Council

The Abu Dhabi Investment Council holds notes in Nscale's $3.36bn pre-IPO raise, beside Third Point, Apollo, Citadel and Nvidia. No British institution appears among the named holders of notes that convert into shares at Nscale's New York listing.

CDP Venture Capital

CDP Venture Capital, the venture arm of Italy's state lender, led TrueLayer's £20.4m round to expand Pay by Bank across Europe. A foreign state investor set the terms on a London fintech round in the same month the British Business Bank mostly followed.

EDBI

Singapore's state investor EDBI joined Universal Quantum's Series A of more than $100m, and the Sussex company is opening its first research centre outside Europe in Singapore. British state money is absent from the largest Series A by a UK quantum company.

Forbion

Forbion co-led OMass Therapeutics' $310m Series C with Bain Capital Life Sciences and Novo Holdings, while the British Business Bank and Syncona followed. The terms of the Oxford spinout's round were set by investors from three countries, none of them Britain.

British Business Bank

The Bank committed £180m to six AI funds on 15 October with no UK-deployment condition, yet led the first close of Microbiotica's £36m Series C. That lead, with Airtel Money choosing London for its £5.3bn debut, is the evidence that British money and markets still set some terms.

Stryker Corporation

Stryker called its roughly $400m CMR Surgical deal its entry into soft-tissue robotics, taking US sales rights for Versius, a board seat and an exclusive option over 100% of the company. The option lets Stryker choose whether and when a Cambridge robot maker becomes part of an American group.

Written with AI from Lowdown's published reporting. Not individually reviewed by an editor. Editorial standards.